Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer

Cancer Microenvironment

Volumn 2, Issue 1, 2009, Pages 59-67

  Yousefieh, Nazita ^a   Hahto, Suzanne M ^a   Stephens, Amber L ^a   Ciavarra, Richard P ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Cancer immunosupression; CCL21; Prostate cancer; T REx system; TRAMP; Tumor microenvironment

Indexed keywords

SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CELL FUNCTION; CONTROLLED STUDY; DISTANT METASTASIS; EFFECTOR CELL; EXPERIMENTAL MODEL; GENE EXPRESSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; LYMPH NODE METASTASIS; METASTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 73449090459     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-009-0021-z     Document Type: Article

References (30)

1. BK Edwards HL Howe LA Ries MJ Thun HM Rosenberg R Yancik PA Wingo A Jemal EG Feigal 2002 Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden Cancer 94 2766 2792 10.1002/cncr.10593 12173348 (Pubitemid 34478095)
2. MD Gunn K Tangemann C Tam JG Cyster SD Rosen LT Williams 1998 A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes Proc Natl Acad Sci U S A 95 258 263 10.1073/pnas.95.1.258 1:CAS:528:DyaK1cXjtl2isg%3D%3D 9419363 (Pubitemid 28103941)
3. B Moser P Loetscher 2001 Lymphocyte traffic control by chemokines Nat Immunol 2 123 128 10.1038/84219 1:CAS:528:DC%2BD3MXhtVOlsLw%3D 11175804 (Pubitemid 33707929)
4. RA Warnock JJ Campbell ME Dorf A Matsuzawa LM McEvoy EC Butcher 2000 The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules J Exp Med 191 77 88 10.1084/jem.191.1.77 1:CAS:528:DC%2BD3cXktFyktQ%3D%3D 10620606 (Pubitemid 30043649)
5. K Willimann DF Legler M Loetscher RS Roos MB Delgado I Clark-Lewis M Baggiolini B Moser 1998 The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7 Eur J Immunol 28 2025 2034 10.1002/(SICI)1521-4141(199806)28:06<2025::AID- IMMU2025>3.0.CO;2-C 1:CAS:528:DyaK1cXjsleit70%3D 9645384 (Pubitemid 28271719)
6. CM Liang CP Zhong RX Sun BB Liu C Huang J Qin S Zhou J Shan YK Liu SL Ye 2007 Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity J Virol 81 9502 9511 10.1128/JVI.00208-07 1:CAS:528: DC%2BD2sXps1amtLg%3D 17567706 (Pubitemid 47311493)
7. L Fan CR Reilly Y Luo ME Dorf D Lo 2000 Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis J Immunol 164 3955 3959 1:CAS:528:DC%2BD3cXis1Wltbc%3D 10754285
8. AP Vicari S Ait-Yahia K Chemin A Mueller A Zlotnik C Caux 2000 Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms J Immunol 165 1992 2000 1:CAS:528:DC%2BD3cXls1KmsL0%3D 10925282
9. ED Kwon BA Foster AA Hurwitz C Madias JP Allison NM Greenberg MB Burg 1999 Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy Proc Natl Acad Sci U S A 96 15074 15079 10.1073/pnas.96.26.15074 1:CAS:528:DC%2BD3cXhtFarsg%3D%3D 10611340 (Pubitemid 30019767)
10. BA Foster JR Gingrich ED Kwon C Madias NM Greenberg 1997 Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model Cancer Res 57 3325 3330 1:CAS:528: DyaK2sXls1ShtLs%3D 9269988
11. RP Ciavarra RR Brown DA Holterman M Garrett WF Glass 2nd GL Wright Jr PF Schellhammer KD Somers 2003 Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer Cancer Immunol Immunother 52 535 545 10.1007/s00262-003-0383-x 1:CAS:528:DC%2BD3sXls1ygu7c%3D 14627125 (Pubitemid 37056128)
12. J Schmielau OJ Finn 2001 Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients Cancer Res 61 4756 4760 1:CAS:528: DC%2BD3MXks1Grtbg%3D 11406548
13. D Krill M Shuman MT Thompson MJ Becich SC Strom 1997 A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates Urology 49 981 988 10.1016/S0090-4295(97)00096-4 1:STN:280:DyaK2szjtFertg%3D%3D 9187716 (Pubitemid 27246978)
14. KD Somers RR Brown DA Holterman N Yousefieh WF Glass GL Wright Jr PF Schellhammer J Qian RP Ciavarra 2003 Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy Int J Cancer 107 773 780 10.1002/ijc.11464 1:CAS:528: DC%2BD3sXovVKjsrk%3D 14566827 (Pubitemid 37339731)
15. RP Ciavarra DA Holterman RR Brown P Mangiotti N Yousefieh GL Wright Jr PF Schellhammer WF Glass KD Somers 2004 Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy J Immunother 27 13 26 10.1097/00002371-200401000-00002 1:CAS:528:DC%2BD3sXpvVShtLY%3D 14676630 (Pubitemid 38076165)
16. Y Latchman CR Wood T Chernova D Chaudhary M Borde I Chernova Y Iwai AJ Long JA Brown R Nunes EA Greenfield K Bourque VA Boussiotis LL Carter BM Carreno N Malenkovich H Nishimura T Okazaki T Honjo AH Sharpe GJ Freeman 2001 PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 261 268 10.1038/85330 1:CAS:528:DC%2BD3MXhvVaksrc%3D 11224527 (Pubitemid 33706004)
17. S Sharma M Stolina J Luo RM Strieter M Burdick LX Zhu RK Batra SM Dubinett 2000 Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo J Immunol 164 4558 4563 1:CAS:528: DC%2BD3cXivFWmt7g%3D 10779757
18. G Escher A Hoang S Georges U Tchoua A El-Osta Z Krozowski D Sviridov 2005 Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages J Lipid Res 46 356 365 10.1194/jlr.D400014-JLR200 1:CAS:528:DC%2BD2MXhvFGku70%3D 15520456 (Pubitemid 40271100)
19. DI Gabrilovich MP Velders EM Sotomayor WM Kast 2001 Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells J Immunol 166 5398 5406 1:CAS:528:DC%2BD3MXjtFyrtL0%3D 11313376
20. M Otsuji Y Kimura T Aoe Y Okamoto T Saito 1996 Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses Proc Natl Acad Sci U S A 93 13119 13124 10.1073/pnas.93.23.13119 1:CAS:528:DyaK28XmvV2rtbo%3D 8917554 (Pubitemid 26382779)
21. CJ Kirk D Hartigan-O'Connor BJ Nickoloff JS Chamberlain M Giedlin L Aukerman JJ Mule 2001 T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy Cancer Res 61 2062 2070 1:CAS:528:DC%2BD3MXit1OgsLw%3D 11280767
22. T Nomura H Hasegawa M Kohno M Sasaki S Fujita 2001 Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes Int J Cancer 91 597 606 10.1002/1097-0215(200002)9999:9999<:: AID-IJC1107>3.0.CO;2-J 1:CAS:528:DC%2BD3MXht1ygsrk%3D 11267967 (Pubitemid 32115251)
23. S Sharma M Stolina L Zhu Y Lin R Batra M Huang R Strieter SM Dubinett 2001 Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma Cancer Res 1 6406 6412
24. JM den Haan SM Lehar MJ Bevan 2000 CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo J Exp Med 192 1685 1696 10.1084/jem.192.12.1685 (Pubitemid 32049762)
25. H Soto W Wang RM Strieter NG Copeland DJ Gilbert NA Jenkins J Hedrick A Zlotnik 1998 The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3 Proc Natl Acad Sci U S A 95 8205 8210 10.1073/pnas.95.14.8205 1:CAS:528: DyaK1cXks1Sms7k%3D 9653165 (Pubitemid 28326091)
26. C Kanegane C Sgadari H Kanegane J Teruya-Feldstein L Yao G Gupta JM Farber F Liao L Liu G Tosato 1998 Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12 J Leukoc Biol 64 384 392 1:CAS:528:DyaK1cXmtVOls7c%3D 9738666
27. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio M (2001) Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 53-63
28. DA Arenberg A Zlotnick SR Strom MD Burdick RM Strieter 2001 The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model Cancer Immunol Immunother 49 587 592 10.1007/s002620000147 1:CAS:528:DC%2BD3MXit1eqsLc%3D 11225989
29. K Koizumi Y Kozawa Y Ohashi ES Nakamura Y Aozuka H Sakurai K Ichiki Y Doki T Misaki I Saiki 2007 CCL21 promotes the migration and adhesion of highly lymph node metastatic human non-small cell lung cancer Lu-99 in vitro Oncol Rep 17 1511 1516 1:CAS:528:DC%2BD2sXmvF2itrs%3D 17487412
30. M Chikazawa K Inoue S Fukata T Karashima T Shuin 2008 Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder Pathobiology 75 335 345 10.1159/000164218 1:CAS:528:DC%2BD1cXhsFarsrzF 19096229